Wind River Studio Enabling Hyundai Mobis and Hyundai AutoEver to Accelerate Development of Next-Gen Intelligent and Connected Vehicles
3.5.2022 13:00:00 EEST | Business Wire | Press release
Wind River®, a global leader in delivering software for mission-critical intelligent systems, today announced that Hyundai Mobis, one of the world’s largest vehicle technology innovators and suppliers, and Hyundai AutoEver has signed an agreement to establish a strategic relationship that includes collaboration with Wind River Studio for the development of an automotive software framework and continuous test and test automation capabilities, as well as advanced software lifecycle management.
“As we move toward a more connected and autonomous future, software is at the center of enabling that reality,” said Avijit Sinha, chief product officer, Wind River. “Wind River Studio can help automotive leaders such as Hyundai Mobis and Hyundai AutoEver achieve a modernized development framework across cloud and edge, combined with software lifecycle management capability to enable them to accelerate their innovation and advance the software defined vehicle.”
“Hyundai Mobis plans to continue to introduce new services by adding future mobility technology to intelligent vehicles through extensive cooperation,” said Chang Jae-ho, senior vice president at Hyundai Mobis.
“Hyundai AutoEver plays the role of software specialist in the Hyundai Motor Group and is leading the team towards digital transformation to revolutionize software development and verification processes throughout vehicle development,” said Kim Seong-woon, vice president, head of the Software Quality Innovation Division at Hyundai AutoEver. “Through close cooperation with Wind River, we will strengthen the function and efficiency of Hyundai AutoEver’s software integrated development environment platform and virtual verification platform to contribute to innovation in vehicle software development by Hyundai Mobis and group companies.”
The auto industry is amid its most significant revolution in more than 100 years. Research from Forbes indicates that automotive leaders believe an intelligent systems approach is central to strategies that can deliver up to a 30% growth in revenue opportunities, and in five years’ time, many of the core requirements for intelligent systems in this industry will need to be in place.1
The collaboration will leverage each company’s specialties and experiences to develop a best-in-class software development infrastructure for next-generation connected automobiles. The companies will work closely on methodologies to accelerate the development and delivery of automotive systems, including enhanced continuous test capabilities and test automation in both simulated and real hardware-based environments and new customer test infrastructures making use of virtual device management.
The Hyundai AutoEver team will play a key role working with Wind River on a software integrated development environment platform and virtual verification platform.
Studio provides a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems. Studio delivers a full lifecycle management platform for intelligent systems at cloud scale. Studio enables development workflows that reduce development costs and accelerate capabilities for building, testing, and deploying on the edge.
More information about Wind River Studio is available at www.windriver.com/studio.
About Wind River
Wind River is a global leader in delivering software for mission-critical intelligent systems. For 40 years, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries, including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class professional services and support and a broad partner ecosystem. To learn more, visit Wind River at www.windriver.com.
About Hyundai MOBIS
Hyundai Mobis is the no.7 global automotive supplier, with annual sales of nearly $30 billion USD. The company was founded in 1977 and is headquartered in Seoul, Korea. Hyundai Mobis aims to become a lifelong technology partner for vehicles and people. The company has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics.
About Hyundai AutoEver
Hyundai AutoEver, a mobility software provider that reliably, efficiently, and innovatively supports software and infrastructure across in-car and out-car areas, builds a mobility software platform to flexibly connect hardware and software, and is creating new value for the upcoming mobility ecosystem.
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005428/en/
Contact information
Jenny Suh
Wind River
510-749-2972
jenny.suh@windriver.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom